TEVA Teva Pharmaceutical Industries Ltd

Shareholder Meeting Notice Teva Pharmaceutical Industries Limited’s Annual Meeting of Shareholders will be held on Thursday, June 15, 2023 at 4:00 p.m. (local time), 9:00 a.m. (Eastern time), at Teva’s Executive Offices, 124 Dvora HaNevi’a Street, Tel Aviv, 6944020, Israel (the “Annual Meeting”). Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. Teva’s Board of Directors recommends that you vote FOR all proposals: 1. Election of Directors A. Dr. Sol J. Barer B. M. Braverman-Blumenstyk C. Janet S. Vergis 2. To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers. 3. To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2024 annual meeting of shareholders. In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2022. PLEASE NOTE—YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to vote at the Annual Meeting through the online meeting platform, you must present your Teva ADSS for cancellation and withdrawal of the corresponding Teva ordinary shares in time to be a shareholder of Teva as of the record date on May 8, 2023. PLEASE NOTE: In order for your ADS votes to be counted, you must be an ADS holder as of May 8, 2023. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. Internet—Go to www.investorvote.com/teva. Phone—Call us free of charge at 1-866-641-4276. Email—Send an email to investorvote@computershare.com with “Proxy Materials Teva Pharmaceutical Industries Limited” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 25, 2023.

The following communication was sent to certain beneficial holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:

The following communication was sent to certain beneficial holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited: Your Vote Counts! TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2023 Annual Meeting Vote by June 13, 2023 11:59 PM ET You invested in TEVA PHARMACEUTICAL INDUSTRIES LIMITED and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 15, 2023. Get informed before you vote View the Form 10-K, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material (s) by requesting prior to May 25, 2023. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.proxyvote.com control # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* June 15, 2023 9:00 AM EST Teva's Executive Offices 124 Dvora HaNevi'a Street Tel Aviv, 6944020, Israel * If you choose to vote these shares in person at the meeting, you must request a " legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. EVA PHARMACEUTICAL INDUSTRIES LIMITED 2023 Annual Meeting Vote by June 13, 2023 11:59 PM ET Voting Items Board Recommends 1. Election of Directors Nominees: 1 A Dr. Sol J. Barer 1 B M. Braverman-Blumenstyk 1 C Janet S. Vergis 2 To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers. 3 To appoint Kesselman and Kesselman, a member of PriceWaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. In addition, shareholders will consider Teva's annual consolidated financial statements for the year ended December 31, 2022. The Annual Meeting will be held at 4:00PM 1ST/9:00AM EST. Shareholders will have the option to listen to the Annual Meeting through an audio webcast. Please check the meeting materials for additional details. For For For For For

The following communication was sent to certain beneficial holders of its ordinary shares by Teva Pharmaceutical Industries Limited:

		TEVA PHARMACEUTICAL INDUSTRIES LIMITED   2023 ANNUAL MEETING OF SHAREHOLDERS June 15, 2023 4:00 p.m. (Israel time) At Teva’s Executive Offices 124 Dvora HaNevi’a Street Tel Aviv, 6944020 Israel   Participation instructions for the Teva Pharmaceutical Industries Limited 2023 Annual Meeting of Shareholders are available in the proxy statement which can be viewed at www.tevapharm.com/2023proxymaterials.

Important Notice Regarding the Availability of Proxy Materials for the

Shareholder Meeting to be Held on June 15, 2023.

Notice is hereby given that the 2023 Annual Meeting of Shareholders (the “meeting”) of Teva Pharmaceutical Industries Limited (“Teva”) will be held at 124 Dvora HaNevi’a Street, Tel Aviv, 6944020, Israel on June 15, 2023 at 4:00 p.m. (Israel time).

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for voting.

The Notice of Annual Meeting of Shareholders and Proxy Statement and Annual Report are available at www.tevapharm.com/2023proxymaterials.

If you want to receive a paper copy or an e-mail with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 25, 2023 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.

Matters intended to be acted upon at the meeting are listed below.

In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2022.

The Board of Directors recommends that you vote FOR all proposals.

To request paper copies of the proxy materials, which include the proxy card,

proxy statement and annual report, please contact us via:

In order to ensure timely delivery, you must request the information no later than May 25, 2023.

2